At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 52 enrolled
Drug / intervention
BIA 9-1067 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating BIA 9-1067, Placebo, and 2 other interventions for Parkinson Disease. Completed, enrolled 52 participants across 1 site.
Detailed Summary
To investigate the effect of BIA 9-1067 in steady-state conditions on the levodopa pharmacokinetics
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesCanada
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
Primary CompletionAug 2009
Study CompletionMar 2010
First PostedFeb 2012
TodayJul 2026
First PostedFeb 15, 2012
Enrollment StartMar 1, 2009
Primary CompletionAug 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.4 years ago
Interventions
BIA 9-1067drug
Placebodrug
levodopa/carbidopadrug
levodopa/benserazidedrug